3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
10
Pulmonary Embolism
4
Venous Thrombosis
3
Neoplasms
3
Thrombosis
2
Multiple Myeloma
2
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Embolism
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Temozolomide
42
Magnetic Resonance Spectroscopy
41
Radiotherapy
22
Specimen Handling
18
Biopsy
13
X-Rays
10
Radiation
10
trametinib
8
Bevacizumab
8
Nivolumab
7
Blood Specimen Collection
7
olaparib
6
fluorodopa F 18
6
dabrafenib
6
Radiotherapy, Intensity-Modulated
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Lomustine
6
pembrolizumab
5
abemaciclib
5
Standard of Care
5
vorasidenib
4
ulixertinib
4
larotrectinib
4
ivosidenib
4
erdafitinib
4
Surgical Procedures, Operative
4
Dianhydrogalactitol
4
Cyclophosphamide
4
Aminolevulinic Acid
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
apixaban
×
1 year
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled